Overexpression, amplification, and androgen regulation of TPD52 in prostate cancer
- PMID: 15172988
- DOI: 10.1158/0008-5472.CAN-03-3881
Overexpression, amplification, and androgen regulation of TPD52 in prostate cancer
Abstract
Gains in the long arm of chromosome 8 (8q) are believed to be associated with poor outcome and the development of hormone-refractory prostate cancer. Based on a meta-analysis of gene expression microarray data from multiple prostate cancer studies (D. R. Rhodes et al., Cancer Res 2002;62:4427-33), a candidate oncogene, Tumor Protein D52 (TPD52), was identified in the 8q21 amplicon. TPD52 is a coiled-coil motif-bearing protein, potentially involved in vesicle trafficking. Both mRNA and protein levels of TPD52 were highly elevated in prostate cancer tissues. Array comparative genomic hybridization and amplification analysis using single nucleotide polymorphism arrays demonstrated increased DNA copy number in the region encompassing TPD52. Fluorescence in situ hybridization on tissue microarrays confirmed TPD52 amplification in prostate cancer epithelia. Furthermore, our studies suggest that TPD52 protein levels may be regulated by androgens, consistent with the presence of androgen response elements in the upstream promoter of TPD52. In summary, these findings suggest that dysregulation of TPD52 by genomic amplification and androgen induction may play a role in prostate cancer progression.
Similar articles
-
PrLZ, a novel prostate-specific and androgen-responsive gene of the TPD52 family, amplified in chromosome 8q21.1 and overexpressed in human prostate cancer.Cancer Res. 2004 Mar 1;64(5):1589-94. doi: 10.1158/0008-5472.can-03-3331. Cancer Res. 2004. PMID: 14996714
-
Tumor protein D52 (TPD52) is overexpressed and a gene amplification target in ovarian cancer.Int J Cancer. 2005 Dec 20;117(6):1049-54. doi: 10.1002/ijc.21250. Int J Cancer. 2005. PMID: 15986428
-
Amplification and overexpression of vinculin are associated with increased tumour cell proliferation and progression in advanced prostate cancer.J Pathol. 2011 Mar;223(4):543-52. doi: 10.1002/path.2828. Epub 2011 Jan 5. J Pathol. 2011. PMID: 21294127
-
Tumor protein D52 (TPD52) and cancer-oncogene understudy or understudied oncogene?Tumour Biol. 2014 Aug;35(8):7369-82. doi: 10.1007/s13277-014-2006-x. Epub 2014 May 6. Tumour Biol. 2014. PMID: 24798974 Review.
-
Evolution of the concept of androgen-sensitive bladder cancer.Scand J Urol. 2013 Jun;47(3):173-8. doi: 10.3109/00365599.2012.756929. Epub 2013 Jan 21. Scand J Urol. 2013. PMID: 23330817 Review.
Cited by
-
The FABP12/PPARγ pathway promotes metastatic transformation by inducing epithelial-to-mesenchymal transition and lipid-derived energy production in prostate cancer cells.Mol Oncol. 2020 Dec;14(12):3100-3120. doi: 10.1002/1878-0261.12818. Epub 2020 Oct 23. Mol Oncol. 2020. PMID: 33031638 Free PMC article.
-
Role of annexin A6 in cancer.Oncol Lett. 2015 Oct;10(4):1947-1952. doi: 10.3892/ol.2015.3498. Epub 2015 Jul 15. Oncol Lett. 2015. PMID: 26622779 Free PMC article.
-
Tumor Protein D53 (TPD53): Involvement in Malignant Transformation of Low-Malignant Oral Squamous Cell Carcinoma Cells.Biomedicines. 2024 Nov 28;12(12):2725. doi: 10.3390/biomedicines12122725. Biomedicines. 2024. PMID: 39767632 Free PMC article.
-
Androgen-dependent alternative mRNA isoform expression in prostate cancer cells.F1000Res. 2018 Aug 3;7:1189. doi: 10.12688/f1000research.15604.1. eCollection 2018. F1000Res. 2018. PMID: 30271587 Free PMC article.
-
Preclinical support for tumor protein D52 as a cancer vaccine antigen.Hum Vaccin Immunother. 2023 Dec 15;19(3):2273699. doi: 10.1080/21645515.2023.2273699. Epub 2023 Oct 30. Hum Vaccin Immunother. 2023. PMID: 37904517 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical